Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer-Reference-Cited by-同舟云学术

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer

Published:2023-11 Issue: Volume:178 Page:27-35
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Zammarrelli William A.,Ma Weining,Espino Kevin,Gordhandas Sushmita,Yeoshoua Effi,Ehmann Sarah,Zhou Qin,Iasonos Alexia,Abu-Rustum Nadeem R.,Aghajanian Carol,Green Angela K.,Rubinstein Maria M.,Makker Vicky

Funder

National Cancer Institute

Memorial Sloan Kettering Cancer Center

National Institutes of Health

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference18 articles.

1. Endometrial cancer;Crosbie;Lancet.,2022

2. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019;Gu;Gynecol. Oncol.,2021

3. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

4. Current evidence-based systemic therapy for advanced and recurrent endometrial Cancer;Gordhandas;J. Natl. Compr. Cancer Netw.,2023

5. Lenvatinib plus Pembrolizumab for advanced endometrial Cancer;Makker;N. Engl. J. Med.,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma;Gynecologic Oncology Reports;2024-10

2. Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis;Frontiers in Immunology;2024-08-09

3. A meta-analysis of the risk of adverse cardiovascular events in patients with cancer treated with inhibitors of the PI3K/AKT/mTOR signaling pathway;2024-08-09

4. Pembrolizumab;Reactions Weekly;2023-10-21